Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 5Pain 4Peripheral Nervous System Diseases 3Neurotoxicity Syndromes 2Colorectal Neoplasms 2Urinary Incontinence 1Prostatic Neoplasms 1Neoplasms 1Musculoskeletal Pain 1Hematologic Neoplasms 1Glioblastoma 1Emergence Delirium 1Drug-Related Side Effects and Adverse Reactions 1Depression 1Cancer Pain 1CIPN 1Acute Pain 1

Interventions

Therapeutics 31Psychiatric Rehabilitation 27Surveys and Questionnaires 15Cognitive Behavioral Therapy 12Early Intervention, Educational 10Psilocybin 9Ketamine 9Methods 8Saline Solution 7Yoga 6Mindfulness-Based Cognitive Therapy 6Interviews as Topic 6Esketamine 6Counseling 6Psychosocial Intervention 5Mindfulness 5Methylphenidate 5Escitalopram 5Educational Status 5Behavior Therapy 5Acupuncture Therapy 5Palliative Care 4Exercise Therapy 4Exercise 4Control Groups 4Caregivers 4Standard of Care 3Psychotherapy 3Niacin 3Mindfulness-Based Stress Reduction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Depression × Duloxetine Hydrochloride × Clear all
NCT02443194 2015-12-03

The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients

Tel-Aviv Sourasky Medical Center

Phase 3 Terminated
50 enrolled
CNS

Depression, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡